Abemaciclib does not increase the corrected QT interval in healthy participants

• Main Authors: Jill C. Chappell (Author), Alan Y. Chiang (Author), Jane Royalty (Author), Hugh Coleman (Author), Palaniappan Kulanthaivel (Author), P. Kellie Turner (Author)
• Format: Book
• Published: Wiley, 2023-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Abemaciclib is an orally administered, potent, and selective small molecule inhibitor of cyclin‐dependent kinases 4 and 6, approved for advanced or metastatic breast cancer. This study aimed to use an exposure-response approach to investigate the effect of abemaciclib and its active metabol...